The tablets are a generic version of the active ingredient found in Luvox which was formerly marketed by Solvay Pharmaceuticals. However, the Luvox brand is no longer available in the market.
Maleate is currently marketed in the US as a selective serotonin (5-HT) reuptake inhibitor (SSRI) class.
“We are extremely pleased to see our portfolio of products growing steadily. We plan to launch this product to the market immediately,” said Daniel Movens, CEO. “This approval brings our total product portfolio to 20 different products, represented by 44 different strengths.”